Aquapharm® is pioneering the search for novel drugs derived from marine microbes that target clinically important human infections.
By utilising its "stress technology" and drug discovery platform the Company is generating a number of exciting hits with strong antibacterial activities. Their primary interests are in the discovery and development of new anti-infectives in the following 2 key areas:
- New antibiotics that target Gram negative infections (both community and hospital acquired)
- New antibiotics to treat multi-drug resistant Gram positive infections (both community and hospital acquired)